UCB’s Europe-approved IL-17 autoimmune drug hits FDA delay

UCB does not have Glob­al En­try for bimek­izum­ab.

While the drug has been cleared in Eu­rope and oth­er re­gions for near­ly two years, UCB’s treat­ment for mod­er­ate to se­vere plaque pso­ri­a­sis has run in­to an­oth­er de­lay in the US.

The Bel­gian drug­mak­er said Tues­day it no longer ex­pects the FDA to make a de­ci­sion about the drug in the third quar­ter of this year. It’s the sec­ond road­block for the ther­a­py af­ter the FDA re­ject­ed bimek­izum­ab in ear­ly 2022, say­ing then that “in­spec­tion ob­ser­va­tions must be re­solved.” In a terse up­date, UCB said the FDA is con­tin­u­ing its re­view, and the reg­u­la­tor “has not com­mu­ni­cat­ed time­lines re­quired to take ac­tion on the ap­pli­ca­tion.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.